New Report Finds 72% of KYC Compliance Professionals Feel Burned Out
January 20, 2022 09:00 ET
|
Kyckr
NEW YORK, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Kyckr has released the findings from their new Voice of the KYC Compliance Professional report. Starting on Oct. 6, 2021, the report surveyed 244...
Oncolyze Announces FDA Orphan Drug Designation for OM-301 for the Treatment of Acute Myeloid Leukemia
January 05, 2022 09:00 ET
|
Oncolyze Inc
NEW YORK, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Oncolyze, Inc, a biotech developing a disruptive technology for the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA)...
Feedzai's market leadership endorsed with category recognition by leading analyst firms
December 20, 2021 05:06 ET
|
Feedzai Inc
SAN MATEO, Calif. and LONDON, Dec. 20, 2021 (GLOBE NEWSWIRE) -- Feedzai, the world’s first RiskOps platform, has been named in the top categories of two analyst firms: Technology Leader in...
Qualigen Therapeutics Promotes Amy Broidrick to President
December 14, 2021 09:18 ET
|
Qualigen Therapeutics, Inc.
Ms. Broidrick to retain title of Chief Strategy Officer CARLSBAD, Calif., Dec. 14, 2021 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a biotechnology company focused on...
Recap and Update of Positive Data from Three Presentations in Patients with TP53 Mutant Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Presented at the 2021 American Society of Hematology (ASH) Annual Meeting
December 14, 2021 08:00 ET
|
Aprea Therapeutics
BOSTON, Dec. 14, 2021 (GLOBE NEWSWIRE) -- Lead investigators from clinical trials evaluating eprenetapopt in patients with TP53 mutant MDS or AML presented positive, updated data at the 2021 ASH...
Aprea Therapeutics Presents Primary Analysis from Phase 2 Trial of Eprenetapopt + Azacitidine for Post-Transplant Maintenance Therapy in TP53 Mutant MDS and AML at the 2021 American Society of Hematology (ASH) Annual Meeting
December 13, 2021 08:00 ET
|
Aprea Therapeutics
60% relapse free survival at 1 year post-transplant79% overall survival at 1 year post-transplantMedian overall survival of 20.6 months BOSTON, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Aprea...
Kura Oncology Reports Preclinical Data Highlighting Synergistic Activity of Menin Inhibitor KO-539 in Combination with Venetoclax
December 13, 2021 07:00 ET
|
Kura Oncology, Inc.
SAN DIEGO, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Immunicum presenterar Fas II-data som visar minskad MRD och förbättrad överlevnad med DCP-001-behandling hos AML-patienter på ASH 2021
December 11, 2021 09:00 ET
|
Immunicum AB
Pressmeddelande Stockholm, 11 december, 2021 Immunicum presenterar Fas II-data som visar minskad MRD och förbättrad överlevnad med DCP-001-behandling hos AML-patienter på ASH 2021 Immunicum AB...
Immunicum Presents Phase II Data Demonstrating Reduced MRD and Improved Survival with DCP-001 Treatment in AML Patients at ASH 2021
December 11, 2021 09:00 ET
|
Immunicum AB
Press Release Stockholm, Sweden, December 11, 2021 Immunicum Presents Phase II Data Demonstrating Reduced MRD and Improved Survival with DCP-001 Treatment in AML Patients at ASH 2021 Immunicum AB...
Jumio Acquiring 4Stop, Redefining the End-to-End Identity Platform
December 07, 2021 06:00 ET
|
FourStop GmbH
KOLN, Germany, Dec. 07, 2021 (GLOBE NEWSWIRE) -- Jumio, the leading provider of AI-powered end-to-end identity orchestration, eKYC and AML solutions, today announced that the company is acquiring...